MACE – Medxy AI

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

news

Evolocumab 预防高风险患者首次发生主要心血管事件

By MedXY 11/13/2025

在 VESALIUS-CV 研究中，与安慰剂相比，evolocumab 将无既往心肌梗死或卒中的动脉粥样硬化或糖尿病患者的首次主要不良心血管事件减少了约 25%（HR 0.75），绝对风险降低幅度较小，随访 4.6 年未发现新的安全性信号。

Cardiology Diabetes & Endocrinology news

Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke

By MedXY 11/13/2025

In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.